Pipeline
Pipeline
Indications | Target | Pipeline | Early Discovery | Preclinical | Phase 1 Clinical Trial | Phase 2 Clinical Trial | Partner |
---|---|---|---|---|---|---|---|
Non-Small Cell Lung Cancer (NSCLC) | EGFR C797S
Mutation |
JIN-A02 Tyrosine kinase inhibitor | - | ||||
HER2 Exon20 insertion Mutation |
JIN-A04 (YH42946) Tyrosine kinase inhibitor |
![]() ![]() |
|||||
EGFR/HER2 Exon20 insertion Mutation |
JIN-A01 Tyrosine kinase inhibitor | - | |||||
Solid Tumor | HSP90 | JIN-001 HSP90 inhibitor | MD Anderson | ||||
Glioblastoma | |||||||
Glioblastoma | HDAC6 | JIN-002 HDAC inhibitor | - | ||||
New | JIN-NOVA AI-based Novel Drug Development Platform | TBD |
![]() |
Indications | Target | Pipeline | Stage | Partner |
---|---|---|---|---|
Non-Small Cell Lung Cancer (NSCLC) | EGFR C797S | JIN-A02 Tyrosine kinase inhibitor |
Phase 1 Clinical Trial US FDA /MFDS IND /TFDA IND Approval1) Orphan Drug Designation Application Submitted2) |
- |
HER2 Exon20 insertion |
JIN-A04 (YH42946) Tyrosine kinase inhibitor |
Preclinical Orphan Drug Designation Application Submitted3), Technology Transfer (to Yuhan Corporation)4) |
![]() |
|
EGFR/HER2 Exon20 insertion | JIN-A01 Tyrosine kinase inhibitor |
Preclinical injury |
- | |
Solid Tumor | HSP90 | JIN-001 HSP90 inhibitor |
Phase 1 Clinical Trial Solid TumorPreclinical Glioblastoma: Collaborative Research with MD Anderson |
MD Anderson |
Glioblastoma | ||||
Glioblastoma | HDAC6 | JIN-002 HDAC inhibitor |
Preclinical |
- |
New | JIN-NOVA AI-based Novel Drug Development Platform |
TBD |
Early Discovery |
![]() |
1) US FDA: Nov 2022 Approval, MFDS : Mar 2023 Approval, Thai FDA : May 2023 Approval
2) Orphan Drug Designation Application Submitted: Aug 2023
3) Orphan Drug Designation Application Submitted: Aug 2022
4) Technology Transfer (to Yuhan Corporation): May 2023